




A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions


Washington State Transactions by Industry

Transaction Amounts per Year



Number of Deals per Sector

*As of 10/2/20



Monthly Highlights

HIGHLIGHTS

- [Athira Pharma](#) announced closing of its initial public offering, raising \$204M. Athira Pharma is currently in late-stage development for its lead therapeutic candidate, NDX-1017, which could halt or reverse the nerve damage resulting from Alzheimer’s disease and other illnesses by using regenerative technology. ([Athira Pharma News](#))
- [Silverback Therapeutics](#) closed an \$85M Series C financing round to support clinical development of TLR8 agonist currently in a Phase I clinical study for treatment of HER2-expressing solid tumors, and to advance the pipeline of other ImmunoTAC therapeutics. ([Business Wire](#))
- [Phase Genomics](#) has received two grants from the National Institutes of Health (NIH) totaling \$3.9M. These grants will fund projects focused on chromosomal abnormalities which can impact fertility and reproduction and with diseases such as cancer. Phase Genomics uses a technology called proximity ligation or Hi-C which allows for a rapid, less expansive analysis of chromosomes using machinery already available in many labs. Phase Genomics launched in 2015 as a spinout from the University of Washington, participating in CoMotion’s incubator and LSW Institute’s WIN Mentoring Program. ([Geekwire](#))

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.



Washington Life Science Transactions

Date	Company	Type	Amount	Date	Company	Type	Amount
1/20/2020	Optimize.health	Equity	\$3,500,000	6/2/2020	eDoula	Convertible Debt	\$50,000
1/23/2020	Athira Pharma	Convertible Debt	\$3,830,000	6/3/2020	AIDA Healthcare	Convertible Debt	\$515,000
1/29/2020	Ventec Life Systems	Equity	\$24,030,000	6/4/2020	Kineta	Equity	\$100,000
1/31/2020	Twistle	Equity	\$18,000,000	6/4/2020	Athira Pharma	Cash	\$85,500,000
1/31/2020	Soovu Labs	Convertible Debt	\$800,000	6/11/2020	Sana Biotechnology	Cash	\$435,000,000
2/1/2020	ActX	Cash	\$5,900,000	6/12/2020	MicrobiomX	Convertible Debt	\$505,000
2/1/2020	Inmedix	ven	undisclosed	6/17/2020	Proprio	Cash	\$23,000,000
2/1/2020	Proteios Technology	Cash	undisclosed	6/22/2020	Oisin Biotechnologies	Equity	\$5,090,000
2/11/2020	Cardiac Insight	Debt	\$8,000,000	6/24/2020	Modento	Equity	\$1,000,000
2/14/2020	Bardy Diagnostics	Cash	\$12,490,000	7/8/2020	LumniThera	Cash	\$14,000,000
2/18/2020	PharmID	Equity	\$5,000,000	7/13/2020	Ulcer Solutions	Equity	undisclosed
2/19/2020	CuraCloud	Cash	undisclosed	7/13/2020	Innovega	Equity	\$2,140,000
2/20/2020	Lupa Bio	Convertible Debt	undisclosed	7/21/2020	Curvafix	Equity	\$10,750,000
2/21/2020	AVM Biotechnology	Equity	\$2,570,000	7/22/2020	Magnolia Neurosciences	Equity	\$5,000,000
2/24/2020	Selkirk Pharma	Equity	\$9,050,000	8/4/2020	Proprio	Equity	\$220,000
2/25/2020	Oisin Biotechnologies	Equity	\$2,970,000	8/6/2020	Xealth	Equity	\$6,000,000
2/26/2020	PVP Biologics		\$3,300,000	8/10/2020	Variant Bio	Equity	\$8,100,000
2/27/2020	WellPepper	Equity	undisclosed	8/12/2020	MicroMend	Convertible Debt	\$4,190,000
2/28/2020	Pacific Rim Outpatient Surgery Center		undisclosed	8/13/2020	Aminex Therapeutics	Convertible Debt	\$2,870,000
3/1/2020	Joylux	Cash	undisclosed	8/20/2020	Optimize.health	Equity	\$15,000,000
3/1/2020	LumniThera	Cash & Equity	undisclosed	8/25/2020	Prescriptive	Equity	\$26,000,000
3/1/2020	Nanodropper	Cash	\$30,000	8/27/2020	Deverra Therapeutics	Equity	\$80,000
3/11/2020	Silverback Therapeutics	Equity	\$78,500,000	9/1/2020	Lumen Bioscience	Equity	\$16,000,000
3/11/2020	OtoNexus Medical Technologies	Equity	\$9,700,000	9/14/2020	Implicit Bioscience	Equity	\$65,551
3/19/2020	Concure Oncology	Cash & Equity	\$7,750,000	9/17/2020	Cyrus Biotechnology	Convertible Debt	\$1,130,000
3/20/2020	Medcurity	Cash & Equity	\$737,500	9/18/2020	Athira Pharma	IPO	\$204,000,000
3/26/2020	Novuson Surgical	Cash & Equity	\$2,380,000	9/23/2020	Silverback Therapeutics	Equity	\$85,000,000
4/1/2020	YouScript	M&A	\$79,300,000	9/25/2020	Immusoft	Equity	\$4,500,000
4/1/2020	Sentinel Healthcare		undisclosed	9/25/2020	Altpep	Equity	\$2,100,000
4/1/2020	SCI Solutions	Cash	\$190,000,000	9/27/2020	Inmedix	Debt and Equity	\$3,500,000
4/2/2020	Blaze Bioscience	Cash & Equity	\$23,230,000	9/28/2020	ImvaqTherapeutics	Equity	\$15,000,000
4/2/2020	Rodeo Therapeutics	Equity	\$8,950,000	9/28/2020	Cardiac Dimensions	Equity	\$17,500,000
4/3/2020	98point6	Cash	\$43,000,000	9/29/2020	TourniTek	Equity	\$10,265
4/6/2020	Juva for Migraine		\$500,000		Total		\$1,698,233,316
4/15/2020	SiDx	Convertible Debt	\$1,250,000				
4/21/2020	welcomehomehealth.com	Equity	\$1,500,000				
4/22/2020	Myosana Therapeutics	Cash	\$1,000,000				
4/26/2020	Avalyn	Cash	\$35,500,000				
5/5/2020	Kineta	Equity	\$5,000,000				
5/18/2020	Nautilus Biotechnology	Cash	\$76,060,000				
5/21/2020	Good Therapeutics	Cash	\$22,340,000				
5/22/2020	MDMetrix	Cash	\$1,150,000				
5/22/2020	Stratos Genomics		undisclosed				
5/22/2020	Tasso	Cash	\$17,000,000				
5/27/2020	Alvaxa Biosciences		undisclosed				

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.